U-47700

# Research Output: U-47700

---

## Chemical Identity

**Molecular formula:** C₁₆H₂₂Cl₂N₂O (confirmed by PubChem CID 71719125 and UNODC) [Ref 34]
**Molecular weight:** 329.3 g/mol [Ref 34]
**SMILES:** `ClC1=C(Cl)C=CC(C(N([C@H]2CCCC[C@@H]2N(C)C)C)=O)=C1` [Ref 34]
**InChIKey:** JGPNMZWFVRQNGU-GJZGRUSLSA-N [Ref 34]
**PubChem CID:** 71719125 (specific to (1S,2S) enantiomer) [Ref 34]
**CAS number:** 82657-23-6 (racemic trans form)
**IUPAC name:** 3,4-dichloro-N-[(1S,2S)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide [Ref 34]
**DEA Code:** 9547

**Discrepancies with seed data:** The brief's seed data had empty fields for SMILES, InChIKey, molecular formula, molecular weight, and PubChem CID. All have now been verified and supplied above. The IUPAC name in the brief ("3,4-dichloro-N-[(1S,2S)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide") matches the PubChem and UNODC entries.

**Stereochemistry note — FLAG FOR HUMAN REVIEW:** The PubChem CID 71719125 and the UNODC database list the (1S,2S) enantiomer; the brief's systematic name matches. However, the DARK Classics review by Kyei-Baffour & Lindsley (2020) [Ref 19] designates the compound as "(1R,2R)," and the vaccine development paper (Park et al. 2023) [Ref 27] also uses (1R,2R). This discrepancy may reflect differing CIP priority assignments when different reference atoms are designated the principal center, or may indicate that different sources are specifying different enantiomers. Both designations refer to the trans isomer. The CAS number 82657-23-6 corresponds to the racemic trans mixture. This needs editorial clarification before generation; the article should not assert which enantiomer is pharmacologically predominant without sourced data.

---

## Pharmacology

### Receptor Binding

U-47700 is a selective full agonist at the mu-opioid receptor (MOR), with measurable but substantially weaker affinity at kappa-opioid (KOR) and delta-opioid (DOR) receptors (Truver et al. 2020 [Ref 20]):

| Receptor | Ki (nM) | Selectivity ratio (vs MOR) |
|----------|---------|--------------------------|
| MOR (μ) | 11.1 | 1.0 (reference) |
| KOR (κ) | 287 | 26 |
| DOR (δ) | 1,220 | 110 |

For comparison, morphine's MOR Ki ≈ 2.7 nM — U-47700 binds MOR with approximately 4-fold lower in vitro affinity than morphine (Truver et al. 2020 [Ref 20]). Despite this, U-47700 is substantially more potent than morphine in vivo (see below), a discrepancy attributable to pharmacokinetic factors including lipophilicity and CNS penetration.

U-47700 acts as a full MOR agonist in the GTPγS functional assay (Baumann et al. 2018 [Ref 5]). In comparative in vitro MOR activation studies, U-47700 and its analog N-ethyl-U-47700 show the strongest activity among non-fentanyl NSOs tested (Vandeputte et al. 2022 [Ref 4]).

The primary metabolite N-desmethyl-U-47700 has an MOR Ki of approximately 206 nM (18-fold weaker), and N,N-didesmethyl-U-47700 has an MOR Ki of approximately 4,080 nM (essentially inactive) (Truver et al. 2020 [Ref 20]). This indicates that the pharmacological activity of U-47700 is almost entirely attributable to the parent compound rather than to its major metabolites.

Molecular docking and dynamics simulations at MOR confirm that U-47700 engages key residues including Trp293 (TM6) and Asp147 (TM3) that are critical for opioid binding; loss of the N-methyl group (forming N-desmethyl-U-47700) disrupts the hydrogen bond with Trp229 (TM5), explaining the dramatically reduced MOR affinity (Laus et al. 2023 [Ref 2]).

### In Vivo Potency

In the hot plate assay (antinociception) in rats, U-47700 had an ED₅₀ of 0.5 mg/kg s.c., approximately 7.5–12-fold more potent than morphine (Kyei-Baffour & Lindsley 2020 [Ref 19]; Truver et al. 2020 [Ref 20]). In mice using the radiant heat tail-flick assay, U-47700 was approximately 12-fold more potent than morphine (Baumann et al. 2018 [Ref 5]). Additional opioid effects observed in rats include dose-dependent catalepsy (ED₅₀ 1.7 mg/kg s.c.) and hypothermia at the 3.0 mg/kg dose (Truver et al. 2020 [Ref 20]). All effects were reversed by naloxone, confirming MOR mediation (Baumann et al. 2018 [Ref 5]).

**Summary of in vivo potency estimate:** 7.5–12× morphine in animal models. No human controlled pharmacology studies exist (Schedule I status precludes this).

### Mechanism of Action

U-47700 acts as a selective, full MOR agonist through the canonical opioid signaling cascade: MOR activation inhibits adenylyl cyclase via Gαi/o coupling, reduces neuronal excitability by opening GIRK channels, and decreases synaptic vesicle release by inhibiting voltage-gated calcium channels. It produces all classical mu-opioid effects: analgesia, euphoria, sedation, respiratory depression, constipation, and miosis (Zawilska 2017 [Ref 16]; Luethi & Liechti 2020 [Ref 17]).

### Pharmacokinetics

**Note:** No published human PK studies exist. All PK data is from animal studies or from computational modeling.

**Rat data (Truver et al. 2020 [Ref 20]):**
- Maximum plasma concentration (Cmax) reached by 15–38 minutes after s.c. injection across all doses
- Plasma concentrations of N-desmethyl-U-47700 and N,N-didesmethyl-U-47700 were delayed but reached levels comparable to the parent compound
- Pharmacodynamic effects correlated with plasma concentrations of parent and N-desmethyl metabolite

**Human PBPK modeling (Zhong et al. 2025 [Ref 1]):**
- First PBPK model for U-47700 built using Caco-2 permeability, tissue-plasma partitioning, plasma protein binding, and human liver microsomal clearance
- Predicted rapid systemic clearance in humans: 0.944–1.371 L/h/kg
- Model validated against rat plasma concentration-time profiles and extrapolated to human via IVIVE and allometric scaling
- Authors note this framework can estimate administration timelines from postmortem samples and assess polydrug interaction risks

### Metabolism

The primary metabolic pathway for U-47700 is sequential N-demethylation:
1. **U-47700 → N-desmethyl-U-47700** (primary reaction; primary metabolite in urine)
2. **N-desmethyl-U-47700 → N,N-didesmethyl-U-47700** (secondary reaction; also detectable)
3. Hydroxylation and combination hydroxylation/demethylation products
4. Phase II conjugation via glucuronidation and sulfation

In total, 12 phase I and 8 phase II metabolites have been identified in human liver microsome incubations (Krotulski et al. 2018 [Ref 21]).

**Enzymes responsible (from human liver microsome studies):**
- **CYP3A4** — primary N-demethylase
- **CYP2B6** — secondary N-demethylase
- **FMO3** — catalyzes N-oxidation (a minor pathway)

N-desmethyl-U-47700 is both the primary urinary biomarker in confirmed intoxication cases and the predominant signal in in vitro microsomal incubations; it is often detectable at higher concentrations than the parent compound in urine (Richeval et al. 2019 [Ref 25]; Krotulski et al. 2018 [Ref 21]). Forensic laboratories are advised to include N-desmethyl-U-47700 and N,N-didesmethyl-U-47700 in screening databases to reduce false-negative results (Richeval et al. 2019 [Ref 25]).

---

## History

### Discovery and Early Development (1970s–1980s)

U-47700 was synthesized by Jacob Szmuszkovicz and colleagues at The Upjohn Company (Kalamazoo, Michigan, USA) as part of a structure-activity relationship program on benzamide opioids aimed at identifying selective MOR agonists with improved analgesic properties and reduced side effects compared to morphine. The compound was first reported in **US Patent 4,098,904** ("Analgesic N-(2-aminocycloaliphatic)benzamides"), filed and granted in **1978** (Szmuszkovicz, The Upjohn Company) [Ref 33]. Additional characterization was published by Szmuszkovicz and von Voigtlander in 1982 and Cheney et al. in 1985. The compound's designation "U-47700" reflects the Upjohn laboratory numbering system; "U" is the company prefix, and 47700 is the compound number.

U-47700 was studied as part of a research program that also produced U-50488 (a selective KOR agonist), U-49900, and other benzamide opioids. U-47700 was never developed into a pharmaceutical product, never received regulatory approval for any medical indication, and was not in clinical or commercial use (Kyei-Baffour & Lindsley 2020 [Ref 19]).

### Emergence on Illicit Markets (c. 2015–2016)

U-47700's ease of synthesis from commercially available precursors, combined with its high potency relative to morphine, led to its emergence as a "research chemical" on internet markets. The compound was first mentioned on a Finnish internet drug discussion forum in **March 2015** (Kriikku et al. 2019 [Ref 7]). It subsequently appeared in markets across the United States and Europe through 2015–2016, typically sold as a white/off-white powder and marketed under street names including **"Pink," "Pinky," "U4,"** and **"Pink heroin."** (Kyei-Baffour & Lindsley 2020 [Ref 19]; Zawilska 2017 [Ref 16]).

U-47700 was found adulterated in counterfeit oxycodone tablets and identified as a key ingredient in the polysubstance mixture known as **"gray death"** — a concrete-powder-like admixture of U-47700, heroin, fentanyl, and carfentanil that appeared in the southeastern United States beginning in early 2017 (Kyei-Baffour & Lindsley 2020 [Ref 19]).

### The Death of Prince (April 2016)

At the autopsy of the musician Prince (Prince Rogers Nelson, d. April 21, 2016), U-47700 was detected in combination with fentanyl. U-47700 was not routinely screened for in clinical or forensic toxicology at that time, and its presence was identified only through specialized analysis (Kyei-Baffour & Lindsley 2020 [Ref 19]). This case raised public and regulatory awareness of U-47700 and non-fentanyl synthetic opioids.

### Regulatory History

A rapid succession of scheduling actions followed widespread fatalities:

| Jurisdiction | Action | Date |
|---|---|---|
| United States | Emergency Schedule I (DEA) | November 14, 2016 [Ref 23] [Ref 30] |
| United States | Permanent Schedule I | April 20, 2018 [Ref 23] |
| International | 1961 Single Convention on Narcotic Drugs, Schedule I | March 2017 (UNCND 60th session) [Ref 34] |
| United Kingdom | Class A, Misuse of Drugs Act 1971 (Amendment Order 2017) | May 31, 2017 [Ref 31] |
| Finland | National control | November 2016 [Ref 7] |
| Canada | CDSA Schedule I | December 2017 [Ref 32] |
| New Zealand | Class A (Misuse of Drugs Act) | December 2022 |

The DEA cited at least **46 confirmed overdose deaths** in New Hampshire, New York, North Carolina, Ohio, Texas, and Wisconsin as the basis for emergency scheduling [Ref 30].

---

## Subjective Effects

**Note:** No controlled human administration studies of U-47700 exist. All subjective effect data is from published non-fatal case reports, forensic/clinical intoxication descriptions, and user self-reports in online harm-reduction communities. This section is labeled accordingly.

Published non-fatal intoxication cases and clinical presentations describe the following:

**CNS depression/opioid toxidrome:**
- Sedation, drowsiness, and loss of consciousness (Schneir et al. 2017 [Ref 22]; Müller et al. 2019 [Ref 18])
- Miosis (pupil constriction) — documented in clinical presentations (Müller et al. 2019 [Ref 18])
- Respiratory depression ranging from bradypnea to apnea (Müller et al. 2019 [Ref 18]; Zawilska 2017 [Ref 16])
- Hypercapnia and arterial hypotension in severe cases (Müller et al. 2019 [Ref 18])
- Analgesia (primary designed effect; extrapolated from animal data and intended pharmacology)

**Sought recreational effects (self-report sources; no controlled studies):**
- Euphoria, described as intense and rapid-onset
- Bodily warmth and heaviness (tactile euphoria)
- Sedation and relaxation (cognitive/emotional suppression)
- Anxiety suppression

**Duration data (insufflation — no controlled human studies; see Gaps & Flags):**
The seed data in the brief (onset 5–10 min, peak 1–2 hr, total 2–3 hr) is not sourced in published literature. Rat data shows Cmax within 15–38 min after s.c. injection (Truver et al. 2020 [Ref 20]). Human PBPK modeling suggests rapid systemic clearance (Zhong et al. 2025 [Ref 1]), consistent with a relatively short duration. Duration values in the brief are flagged for editorial review — they are structurally plausible given the compound's pharmacokinetics but are not confirmed in any published human study.

---

## Safety & Toxicity

### Overview

U-47700's toxicity profile is primarily defined by its high potency, steep dose-response curve, and respiratory depression at doses close to the analgesic dose — a narrow therapeutic index that creates substantial overdose risk (Kyei-Baffour & Lindsley 2020 [Ref 19]).

### Fatal Blood Concentrations

Multiple large postmortem series have been published. Key blood concentration data:

| Study | N | Matrix | Range | Median/Mean |
|---|---|---|---|---|
| Fels et al. 2019 [Ref 6] | 26 | Femoral blood | 27–2,200 ng/mL | 610 ng/mL (median) |
| Mohr et al. 2016 [Ref 12] | 20 | Blood | 17–490 ng/mL | 253 ng/mL (mean) |
| Kriikku et al. 2019 [Ref 7] | 10 | Blood | 150–2,000 ng/mL | 300 ng/mL (median) |
| McIntyre et al. 2017 [Ref 14] | 1 | Peripheral blood | 190 ng/mL | — |

Note: The broad concentration range reflects polydrug use (polysubstance cases may die at lower U-47700 concentrations), postmortem redistribution, and variable analytical methods. Central-to-peripheral blood ratio reported as approximately 1.8:1 (McIntyre et al. 2017 [Ref 14]).

**Non-blood matrices (Strehmel et al. 2018 [Ref 10]):**
- Liver: 9.9 µg/g
- Bile fluid: 2.3 µg/mL
- Heart blood: 1.25 µg/mL
- Urine: 0.24 µg/mL
- Gastric contents: 0.57 µg/mL
- CSF: 0.4 µg/mL
- Hair: 0.14 ng/mg

### LD50

No published LD50 data in humans. No formal animal LD50 study has been published. **FLAG for human review** — the brief's statement "high toxicity relative to its dose due to its extreme potency" is clinically supported by the fatality case series but no formal toxicological LD50 value has been established and published.

### Mechanism of Death

In all documented fatalities, cause of death was **respiratory depression** leading to hypoxic respiratory failure, with asphyxiation and cardiac arrest as the terminal events. This is the canonical mechanism of mu-opioid overdose. Polysubstance use (particularly combination with CNS depressants including designer benzodiazepines) was present in the majority of cases (Fels et al. 2019 — 15/26 polysubstance; Kriikku et al. 2019 — majority polysubstance) [Ref 6] [Ref 7].

### Epidemiology of Deaths

- **Germany:** 26 fatalities recorded April 2016 – August 2017; 25/26 male; mean age 34 years; 15/26 involved co-use of other NPS (synthetic cannabinoids, stimulants, designer benzodiazepines) (Fels et al. 2019 [Ref 6])
- **Finland:** 10 fatalities; 2 more found on retrospective data re-analysis; drug present on market from March 2015 to 2017 "toxic lifespan" (Kriikku et al. 2019 [Ref 7])
- **United States (CDC, 2016):** 40/5,152 opioid overdose deaths in 10 states (July–Dec 2016); 80% male; 90% non-Hispanic white; median age 32 years; 60% also positive for fentanyl (O'Donnell et al. 2017 [Ref 24])
- DEA cited at least **46 confirmed deaths** by November 2016 [Ref 30]
- **Canada (Quebec):** Multiple polysubstance fatalities identified, including co-detection with furanylfentanyl and 4-ANPP (Garneau et al. 2020 [Ref 8])

### Selected Individual Case Reports

- **McIntyre et al. 2017 [Ref 14]:** Male with drug abuse history found unresponsive; insufflation paraphernalia at scene; U-47700 peripheral blood 190 ng/mL; co-ingestion alprazolam 0.12 mg/L; cause of death: acute U-47700 and alprazolam abuse.
- **Strehmel et al. 2018 [Ref 10]:** First reported fatal case via **intravenous** injection (rather than insufflation); high purity powder confirmed by NMR; novel matrix data including CSF and hair concentrations.
- **Ellefsen et al. 2017 [Ref 11]:** Multi-drug fatality combining 3-FPM (stimulant), U-47700, amitriptyline, methamphetamine, and two designer benzodiazepines (flubromazolam, delorazepam).
- **Walsh et al. 2019 [Ref 15]:** 33-year-old revived at scene, died 6 days later in ICU; mitragynine co-detected; case highlights value of drug paraphernalia analysis.
- **Schneir et al. 2017 [Ref 22]:** Non-fatal near-death case with laboratory confirmation; first published clinical description of U-47700 opioid toxidrome.

### Non-Standard Detection Concerns

U-47700 is not detected by standard immunoassay opioid screens (which target morphine/codeine or specific fentanyl analogs). Specialized LC-MS/MS or QTOF-MS methods are required (Mohr et al. 2016 [Ref 12]; Moody et al. 2018 [Ref 29]; Jung et al. 2020 [Ref 28]). This contributed to under-detection in early surveillance and is a documented harm-amplification factor.

---

## Harm Reduction

### Naloxone Response

U-47700, as a MOR agonist, is reversible by naloxone. In the non-fatal case report by Schneir et al. 2017 [Ref 22], naloxone administration reversed the opioid toxidrome. In animal studies, all antinociceptive and behavioral effects were naloxone-reversible (Baumann et al. 2018 [Ref 5]). However, standard naloxone doses used for heroin overdose (0.4 mg) may be insufficient given U-47700's high potency; multiple doses or higher initial doses may be required — consistent with reports from gray death cases, where up to 10 naloxone doses have been needed (web-reported, not peer-reviewed for gray death specifically).

The primary naloxone treatment guidance for opioid overdose (Saari et al. 2024 [Ref 36 — not yet in registry]) remains applicable; titrate to respiration restoration (not consciousness).

### Dose Accuracy and Potency Hazard

The primary harm-reduction concern for U-47700 is the extreme potency combined with poorly standardized street supply. Doses from ~1 mg threshold to ~10 mg heavy represents a 10-fold range. Inaccurate weighing of a substance with LD-proximate doses in the low-mg range is extremely dangerous. No fentanyl test strips distinguish U-47700 (though reagent testing — Mecke, Marquis, Simon's — may show characteristic color responses).

### Polysubstance Interaction Risks

The majority of U-47700 fatalities involved polysubstance use. CNS depressant combinations (alcohol, benzodiazepines, other opioids) are documented in fatal cases and represent the highest risk (Fels et al. 2019 [Ref 6]; Ellefsen et al. 2017 [Ref 11]). The interactions listed in the brief (Alcohol: lethal; GBL/GHB: lethal; Tramadol: lethal; Ketamine: lethal) are consistent with the published case evidence showing polydrug deaths and with the known pharmacological mechanism of additive CNS depression, but specific interaction studies for each pairing do not exist in the published literature. **FLAG: All interaction severity ratings should be reviewed against each specific pair's published evidence; most are inferred from opioid class + CNS depressant additive effects rather than U-47700-specific interaction studies.**

### Gray Death

"Gray death" is a polysubstance mixture containing variable proportions of U-47700, heroin, fentanyl, and carfentanil; it first appeared in the southeastern United States (Alabama, Georgia) in early 2017. Its extreme potency (driven by carfentanil) and variable composition make it acutely fatal on first contact; some powdered forms are dermal-exposure hazards for first responders (Kyei-Baffour & Lindsley 2020 [Ref 19]).

---

## Tolerance & Dependence

### Tolerance

U-47700 is expected to produce rapid MOR tolerance through the same mechanisms as other full mu-opioid agonists (receptor internalization, β-arrestin recruitment, CREB-mediated transcriptional changes). No published controlled tolerance studies specific to U-47700 in humans or animals have been found. The seed data tolerance values (buildup: "develops with prolonged and repeated use," half-life for tolerance: 5 days, full reset: 1.5 weeks) are consistent with general opioid tolerance pharmacology but are not supported by any U-47700-specific published study. **FLAG: These values are opioid-class inferences, not U-47700-specific data.**

Cross-tolerance with other MOR agonists (other opioids) is expected given shared receptor mechanism (Zawilska 2017 [Ref 16]).

### Dependence

**Physical dependence:** Characteristic opioid withdrawal syndrome is expected with prolonged use. No published case reports of U-47700-specific withdrawal management were found. Given U-47700's high potency, physical dependence may develop rapidly.

**Psychological dependence:** U-47700's high euphoric potency and rapid onset (insufflated) make it consistent with high addiction liability. No formal addiction liability assessments using DSM criteria or similar tools have been published.

**Treatment:** No U-47700-specific pharmacotherapy trials exist. Buprenorphine, methadone, and naltrexone would theoretically apply given shared MOR mechanism, but no published case reports were found documenting opioid agonist therapy for U-47700 use disorder.

**Vaccine research:** Park et al. 2023 [Ref 27] developed and characterized a rodent vaccine against U-47700 that produced sub-micromolar antibody affinity and prevented BBB penetration in rodents, representing a proof-of-concept for immunopharmacotherapy. No clinical data exists.

---

## Interactions

**Warning:** The interactions below are documented or inferred from published case reports and opioid class pharmacology. Specific pharmacokinetic interaction studies (CYP inhibition/induction with specific co-drugs) do not exist in the published literature for U-47700.

### CNS Depressants (High Mortality Risk)

All CNS depressants produce additive or synergistic respiratory depression with MOR agonists. This is the dominant mechanism of polysubstance opioid overdose death.

- **Benzodiazepines:** Multiple fatal cases document co-ingestion of designer benzodiazepines (flubromazolam, diclazepam) with U-47700 (Ellefsen et al. 2017 [Ref 11]; McIntyre et al. 2017 [Ref 14]). Classic benzodiazepines (alprazolam, diazepam) also implicated. Combination is documented as directly lethal.
- **Alcohol:** Additive CNS and respiratory depression; lethal interaction consistent with general opioid-alcohol pharmacology.
- **GHB/GBL:** Both are CNS depressants with strong GABA-B agonism and some opioid system interaction; additive respiratory depression expected; listed as lethal in seed data (consistent with class pharmacology).
- **Ketamine:** CNS depressant at anesthetic doses; combination with opioids has documented respiratory depression risk; seed data lists as lethal.
- **Other opioids (tramadol, other synthetic opioids):** Additive MOR depression; tramadol additionally has serotonergic and noradrenergic activity; listed as lethal in seed data, consistent with published polydrug opioid fatality data.
- **Nitrous oxide:** Seed data lists as unknown; N₂O has weak opioid properties (endorphin release); no published U-47700-specific interaction data found.

### CYP-Based Drug Interactions

Because U-47700 is metabolized primarily by **CYP3A4 and CYP2B6** (with FMO3 contribution), inhibitors of these enzymes could substantially increase U-47700 plasma concentrations:
- **CYP3A4 inhibitors** (ketoconazole, clarithromycin, grapefruit juice, ritonavir): expected to increase U-47700 exposure
- **CYP3A4 inducers** (rifampicin, carbamazepine, St John's Wort): expected to reduce U-47700 exposure and potentially precipitate withdrawal in dependent users

**No published CYP interaction studies specific to U-47700 exist.**

### Serotonin Syndrome Risk

U-47700 does not appear to have published serotonergic activity. However, tramadol (listed as a known interaction) is a serotonin-norepinephrine reuptake inhibitor and could theoretically produce serotonin syndrome in combination with serotonergic drugs. Specific serotonin syndrome risk from U-47700 itself has not been documented.

---

## Legal Status

| Jurisdiction | Status | Schedule/Class | Date |
|---|---|---|---|
| United States | Schedule I (DEA) | Controlled Substances Act [Ref 23] [Ref 30] | Temporary: Nov 14, 2016; Permanent: Apr 20, 2018 |
| United Kingdom | Class A | Misuse of Drugs Act 1971 (Amendment Order 2017) [Ref 31] | May 31, 2017 |
| International | Schedule I | 1961 Single Convention on Narcotic Drugs [Ref 34] | March 2017 |
| Canada | Schedule I | Controlled Drugs and Substances Act [Ref 32] | December 2017 |
| Finland | National control | — | November 2016 [Ref 7] |
| New Zealand | Class A | Misuse of Drugs Act 1975 | December 2022 |
| Germany | Controlled | BtMG (Anlage I) | ~2016 (exact date not confirmed in published sources) |

**Analog act:** In the United States, U-47700 is now Schedule I, making analog act applicability moot; prior to November 2016, it may have been subject to the Federal Analogue Act based on structural and pharmacological similarity to morphine, though this was not legally tested in published reports.

---

## Clinical Trials

No registered clinical trials were found for U-47700 on ClinicalTrials.gov. This is expected for a Schedule I substance with no approved therapeutic indication and high abuse/lethality potential. The only prospective human research context would require DEA Schedule I researcher registration, which is highly restrictive.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Safety-Critical Values Requiring Human Review

1. **FLAG — Dose ranges not confirmed in controlled human studies.** The brief's dose data (Threshold: 1 mg, Light: 4–6 mg, Common: 6–8 mg, Strong: 8–10 mg, Heavy: 10+ mg, all insufflated) are community-sourced estimates. No controlled human dosing study exists. Given that fatal postmortem blood concentrations range from 17 ng/mL to 2,200 ng/mL and the compound is 7.5–12× more potent than morphine, dose accuracy is safety-critical. The generation agent should preserve these values (best available evidence) but clearly label them as community consensus estimates, not clinically validated.

2. **FLAG — Duration data not confirmed in controlled human studies.** Onset 5–10 min, peak 1–2 hr, total 2–3 hr are plausible based on PBPK modeling and rat PK data but have not been validated in humans. These should be labeled as estimated / community consensus.

3. **FLAG — Tolerance half-life (5 days) and full reset (1.5 weeks) not source-verified.** These values are consistent with general opioid tolerance pharmacology but no U-47700-specific published study supports them. Label as class-inference.

4. **FLAG — Interaction severity ratings (Ketamine: lethal, Tramadol: lethal, Nitrous: unknown, PCP: unknown) not supported by U-47700-specific published studies.** They represent pharmacological class inferences or single-drug class data. "Lethal" for PCP specifically is unsupported; PCP is not a CNS depressant in the typical sense — it is a dissociative that can produce stimulant-like effects. This interaction severity should be critically reviewed.

5. **FLAG — No published LD50 data for U-47700 in any species.** Formal LD50 determination has not been published. Toxicity is documented through postmortem case series, not controlled toxicological studies.

6. **FLAG — Stereochemistry discrepancy.** PubChem CID 71719125 and UNODC list the (1S,2S) enantiomer; Kyei-Baffour & Lindsley 2020 [Ref 19] and Park et al. 2023 [Ref 27] designate the compound as (1R,2R). The brief's systematic name uses (1S,2S). This may reflect different naming conventions for the same compound (both describe the trans isomer) or may indicate that sources are specifying different enantiomers. The pharmacologically most active enantiomer is not definitively established in the published literature. Needs editorial review before generation.

7. **FLAG — SMILES, InChIKey, CID were missing from seed data.** All have been populated above from PubChem and UNODC. The generation agent should use these verified values.

8. **FLAG — No published data on U-47700 withdrawal syndrome, treatment protocols for U-47700 use disorder, or formal dependence/addiction liability studies.** All dependence data in the brief is class-level inference. The brief's "moderate" physical and psychological dependence ratings are plausible but not substance-specific.

### Data Absent from Published Literature

- No human bioavailability or pharmacokinetic data (oral, intranasal, IV) for U-47700 from clinical studies
- No published data on protein binding in humans (only from PBPK model inputs)
- No published data on respiratory depression dose threshold in humans
- No published data on teratogenicity or reproductive toxicity for U-47700 specifically
- No published data on cardiac toxicity (QT prolongation etc.)
- No published studies on long-term sequelae of non-fatal U-47700 intoxication
- No published harm reduction clinical guidelines specific to U-47700
- No published data on oral bioavailability in humans (animal data absent from literature found)

### Unresolved

- The CAS number 82657-23-6 corresponds to the racemic trans form; the PubChem CID 71719125 corresponds to the (1S,2S) enantiomer only. The specific enantiomeric purity of street samples has not been systematically studied in the published literature.
- The "PCP: unknown" interaction severity should be cross-checked against any published data on opioid + NMDA antagonist interactions more broadly.
- Australia's specific scheduling date and schedule number for U-47700 under the SUSMP (Therapeutic Goods Act) was not confirmed from primary regulatory sources; the Novachem Australia reference product listing suggests it is controlled, but the exact scheduling date requires confirmation from TGA records.